Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.09
-0.23 (-3.14%)
At close: Apr 28, 2026, 4:00 PM EDT
7.18
+0.09 (1.27%)
After-hours: Apr 28, 2026, 7:19 PM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 14, with a low estimate of 6.00 and a high estimate of 22. The average target predicts an increase of 97.46% from the current stock price of 7.09.
Analyst Consensus: Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Seres Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 | Strong Buy | Maintains | $22 | +210.30% | Mar 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $22 | Strong Buy | Maintains | $14 → $22 | +210.30% | Sep 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -15.37% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +252.61% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | +111.57% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
n/a
from 789.00K
Revenue Next Year
n/a
EPS This Year
-8.39
from 0.64
EPS Next Year
-9.35
from -8.39
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -8.64 | -9.63 | |
| Avg | -8.39 | -9.35 | |
| Low | -8.07 | -8.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.